Navigation Links
New Drug-Coated Stent Does Well in Early Trial
Date:4/22/2008

But doctors want more data, and device not yet approved for use in U.S.

TUESDAY, April 22 (HealthDay News) -- A new kind of drug-coated stent was better at keeping arteries open than an older stent in the first large-scale U.S. study of the device, researchers report.

"This study suggests that in terms of overall safety and effectiveness, the Xience stent is superior to the Taxus stent, in terms of reduction of major cardiovascular events such as heart attacks at the time of the procedure," said study author Dr. Gregg W. Stone, director of cardiovascular research and education at the Center for Interventional Vascular Therapy, New York-Presbyterian Hospital/Columbia University Medical Center.

But, Stone added, "it is still too early to say whether this translates into a reduction of overall deaths. All we can say is that it is superior to the Taxus stent with a one-year follow-up."

The findings are published in the April 23/30 issue of the Journal of the American Medical Association.

The Xience stent, developed by a division of Abbott Laboratories, is not yet available for use in the United States. An advisory panel of the U.S. Food and Drug Administration has recommended approval, and action is expected later this year.

If approved, the Xience stent would be the fourth drug-coated stent on the American market. It would compete with the Cypher, which is coated with the drug sirolimus and marketed by Johnson and Johnson; Taxus, a Boston Scientific product coated with paclitaxel; and the newest entry, Medtronic's Endeavor, coated with ABT-578, a chemical relative of sirolimus. The Xience stent is coated with a drug called everolimus.

All the drug-coated stents are designed to reduce the risk that the opened coronary artery will close again. It's not yet possible to say which one is superior, Stone said.

"It's very difficult to rank them 1, 2, 3, 4," he said. "That will be a personal decision based on performance, price and each physician's interpretation of the data."

But the Xience stent does have advantages, because both the stent itself and its drug coating are thinner than other products, Stone said. "In addition to this study, which suggested a better outcome, it is also flexible and easily usable, which makes it a very attractive option for physicians," he said.

The study was financed by Abbott. The journal report noted that the company had "the right to a nonbinding review of the manuscript," but that "approval of the sponsor was not required prior to submission."

"They did not have final approval as to what I wrote in this manuscript," Stone said.

In the study, 669 people with blocked coronary arteries were given the Xience stent and 333 got the Taxus stent. At nine months, 7.2 percent of the arteries with the newer stent had closed again, compared to 9 percent of those with the paclitaxel-coated stent. The overall incidence of major adverse events such as heart attacks at 12 months was 6 percent among the people getting the Xience stent and 10.3 percent in those getting the Taxus stent.

Dr. Manesh R. Patel, assistant professor of medicine at Duke University School of Medicine and co-author of an accompanying editorial in the journal, called the new research a good start but said the review process is still unfolding.

"We have to be careful in what we recommend," Patel said. "What we have now is information in this study that the everolimus-eluting stent is slightly better than the paclitaxel stent out to one year. We don't know the long-term results."

The people in the trial had relatively simple artery blockages, Patel noted. "In those patients, there was a clinical benefit, small but significant, but we need to be cautious as we apply it to a wider array of patients," he said.

The FDA has asked for a longer follow-up review of the new stent, which is appropriate, Patel said. "There is a possibility of a step forward, but I await future studies," he said. "I want to have the data in before I say that this one overtakes the other one."

More information

A review of drug-coated stents is offered by the U.S. Food and Drug Administration.



SOURCES: Gregg W. Stone, M.D., director, cardiovascular research and education, Center for Interventional Vascular Therapy, New York-Presbyterian Hospital/Columbia University Medical Center, New York City; Manesh R. Patel, M.D., assistant professor, medicine, Duke University School of Medicine, Durham, N.C.; April 23/30, 2008, Journal of the American Medical Association


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Drug-Coated Stents Go Head to Head
2. Study Finds Benefits With Drug-Coated Stents
3. Drug-Coated Stents No Riskier in Long Run Than Bare Metal Ones
4. Drug-Coated Stents Better Than Bare-Metal Ones in Complex Cases
5. Drug-Coated Balloons Keep Leg Arteries Open: Study
6. Drug-coated balloon overcomes in-stent restenosis
7. Investigators uncover intriguing clues to why persistent acid reflux sometimes turns into cancer
8. Nanowire coating for bone implants, stents
9. Data from Patient Subsets of e-HEALING, a Worldwide Registry, Support Use of OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM) as Alternative to Drug- Eluting Stents
10. Majority of 2.4 Million U.S. Children With ADHD Not Diagnosed or Consistently Treated, According to New Gold Standard Study by Cincinnati Childrens Researchers
11. Public Health and Need for Consistent Standards Preclude Exception for Breastfeeding Mother in National Medical Licensing Test
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... ... May 02, 2016 , ... As directed by its board of ... issues its full support to allow certified nurse practitioners (CNP) to practice to the ... worked under such supervision for three years and 3,600 hours. , In addition, HAP ...
(Date:5/2/2016)... ... 02, 2016 , ... Amica Life Insurance Company has unveiled ... throughout various life stages. , The site launched on April 1, and it ... specific to the times when life insurance matters most. , “Through our research, ...
(Date:5/2/2016)... ... ... Dr. Philip Shindler, dentist in Agoura Hills , now offers E4D ... necessary dental treatments could require multiple appointments to complete. This could mean taking time ... Not only could this be inconvenient, but it could also be overwhelmingly unpleasant for ...
(Date:5/2/2016)... ... May 02, 2016 , ... Further establishing itself as a leader in natural ... Variety Value Boxes were selected from over 1,000 entrants as a winner and recipient ... natural dental chews for dogs are a favorite product among pet-parents worldwide, as each ...
(Date:5/2/2016)... NEW PORT RICHEY, Fla. (PRWEB) , ... ... ... Pharmacology experts and medical researchers report that many commonly used prescription medications, ... memory loss (1). To mitigate these risks, Novus Medical Detox Center ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... April 28, 2016 TapImmune,Inc. ... innovative peptide and gene-based immunotherapeutics and vaccines for the treatment ... presenting at the 3rd Annual Growth Capital Expo ... , 2016 at Caesars Palace in Las Vegas, Nevada.  ... Wednesday, May 4 th by Dr. John N. ...
(Date:4/27/2016)... PARIS , le 27 Avril 2016 /PRNewswire/ ... chiffre d,affaires a progressé de +5% sur le ... ventes récurrentes de consommables  Croissance de ... Mauna Kea Technologies (Euronext : ... multidisciplinaire d,endomicroscopie confocale laser, annonce aujourd,hui son chiffre ...
(Date:4/27/2016)... 27, 2016   Zillion Group today ... technology platform, which specializes in live video consultation. ... digital products, Zillion enables companies to realize the ... to take control of their health. ... – including one-to-one, group and webcast scheduled or ...
Breaking Medicine Technology: